Leber Hereditary Optic Neuropathy (Lhon) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disorder characterized by acute or subacute bilateral visual loss due to selective degeneration of retinal ganglion cells (RGCs) and their axons forming the optic nerve. First described by Theodor Leber in 1871, LHON is caused by point mutations in mitochondrial DNA (mtDNA) encoding subunits of complex I (NADH:ubiquinone oxidoreductase) of the [mitochondrial] respiratory chain. LHON is the most common inherited mitochondrial optic neuropathy and serves as a paradigmatic model for understanding how [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX-- leads to neuronal death in [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. The disease predominantly affects young males (median onset age 20–30 years), though incomplete penetrance and environmental modifiers create substantial variability in disease expression.
LHON prevalence varies across populations:
| Region | Prevalence | Source |
|---|---|---|
| United Kingdom (North East England) | 1 in 31,000 | Man et al., 2003 [1] |
| Finland | 1 in 50,000 | Puomila et al., 2007 [2] |
| Denmark | 1 in 54,000 | Rosenberg et al., 2016 |
| Japan | 1 in 50,000 | Ueda et al., 2017 |
| Australia | 1 in 68,000 | Mackey et al., 1992 |
Over 90% of LHON cases worldwide are caused by one of three point mutations in mitochondrial complex I subunit genes:
| Mutation | Gene | Complex I Subunit | Frequency | Prognosis |
|---|---|---|---|---|
| m.11778G>A | MT-ND4 | ND4 | ~70% | Poorest; spontaneous recovery ~4% |
| m.14484T>C | MT-ND6 | ND6 | ~13% | Best; spontaneous recovery ~37–58% |
| m.3460G>A | MT-ND1 | ND1 | ~14% | Intermediate; spontaneous recovery ~15–25% |
These three mutations are classified as "primary" because they are sufficient to cause disease (Newman et al., 1991 [4]; Mackey et al., 1996 [5]).
Additional rarer primary mutations have been identified in MT-ND1, MT-ND2, MT-ND3, MT-ND4L, MT-ND5, and MT-ND6, collectively accounting for the remaining ~3–5% of LHON cases.
Approximately 10–15% of LHON patients are heteroplasmic (carrying a mixture of mutant and wild-type mtDNA). Higher levels of mutant mtDNA (>60–80%) correlate with increased disease penetrance. Rapid segregation of mtDNA heteroplasmy between generations can explain variable clinical expression within families.
The incomplete penetrance and male predominance of LHON indicate the existence of nuclear genetic modifiers:
All three primary LHON mutations affect subunits of respiratory chain complex I:
Reduced electron transfer efficiency: The mutations impair the ability of complex I to transfer electrons from NADH to ubiquinone, reducing oxidative phosphorylation efficiency by 25–70% depending on the mutation (Brown et al., 2000 [6]).
Increased [reactive oxygen species ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production: Impaired electron flow through complex I leads to electron leakage and superoxide generation, creating [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- that damages mitochondrial and cellular components.
ATP depletion: Reduced complex I activity decreases the proton gradient across the inner mitochondrial membrane, limiting ATP synthesis through ATP synthase (complex V).
RGCs are uniquely vulnerable to mitochondrial dysfunction due to:
High metabolic demand: The optic nerve head is one of the most metabolically active regions in the CNS. RGC axons in the retinal nerve fiber layer are unmyelinated before reaching the lamina cribrosa, requiring enormous energy expenditure for action potential propagation along exposed axons.
Papillomacular bundle vulnerability: The smallest-caliber RGC axons in the papillomacular bundle (serving central vision) have the highest density of mitochondria and are the first to degenerate in LHON, explaining the characteristic centrocecal scotoma.
Long axonal length: RGC axons extend from the retina through the optic nerve to the lateral geniculate nucleus, requiring efficient [axonal transport[/mechanisms/[axonal-transport-defects[/mechanisms/[axonal-transport-defects[/mechanisms/[axonal-transport-defects--TEMP--/mechanisms)--FIX-- and distributed mitochondrial energy supply.
Limited capacity for mitochondrial biogenesis: Compared with other neuronal populations, RGCs have relatively limited ability to compensate for respiratory chain dysfunction through increased mitochondrial biogenesis.
RGC degeneration in LHON involves multiple death pathways:
Acute/subacute phase: Painless, progressive visual loss beginning in one eye, followed by involvement of the second eye within days to months (mean interval: 6–8 weeks). Visual acuity typically deteriorates to 20/200 or worse.
Fundoscopic findings: During the acute phase, characteristic findings include:
Visual field defects: Dense centrocecal scotoma (central or cecocentral visual field loss) with relative preservation of peripheral vision.
Chronic phase: Progressive optic atrophy with temporal pallor of the optic disc, thinning of the retinal nerve fiber layer (especially the temporal quadrant), and permanent visual deficit in most patients.
Some LHON patients develop additional neurological features beyond optic neuropathy:
Diagnosis is suspected based on:
Confirmation requires molecular genetic testing of mtDNA:
OCT provides quantitative assessment of retinal nerve fiber layer (RNFL) thickness:
Idebenone, a synthetic short-chain analogue of coenzyme Q10, is the only approved treatment for LHON (EU approval 2015):
[Gene therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX-- represents the most promising emerging treatment for LHON:
Allotopic expression: The MT-ND4 gene is re-engineered with a nuclear genetic code and a mitochondrial targeting sequence, packaged into an adeno-associated virus (AAV2) vector, and delivered via intravitreal injection. The protein product is imported into mitochondria to restore complex I function.
GenSight Biologics (GS010/lenadogene nolparvovec): Phase III trials (REVERSE, RESCUE, REFLECT) demonstrated bilateral visual improvement following unilateral intravitreal injection, suggesting transfer of therapeutic benefit to the untreated eye (Yu-Wai-Man et al., 2020 [8]).
Huatai Biopharmaceutical: NR082 (rAAV2-ND4), approved in China in 2024 for LHON caused by the m.11778G>A mutation, representing the first approved gene therapy for a mitochondrial disease.
Carriers should be counseled to avoid environmental triggers that may precipitate visual loss:
The study of Leber Hereditary Optic Neuropathy (Lhon) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.